ChemoCentryx, Inc.

Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to

Are you a current or former employee of the company?*YesNo


+Additional Purchases


+Additional Sales

If you prefer, you may submit your transaction information or comments/questions in the box below:

There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.

We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at, or by email at

If you choose to take no action, you can remain an absent class member.

Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.

The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

Portnoy Law Firm
Lesley F. Portnoy, Esq.,
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067

It is alleged in this complaint that ChemoCentryx made misleading and false statements to the market. ChemoCentryx designed the study of its Phase III ADVOCATE trial in a manner that created issues relating to the interpretability of trial data to define a clinically meaningful benefit of avacopan. This trial data presented serious safety concerns in relation to avacopan. These problems combined to form a deep concern in regard to the viability of ChemoCentryx’s New Drug Application for avacopan for the treatment of ANCA-associated vasculitis. Throughout the class period, ChemoCentryx’s public statements were false and materially misleading based on these facts. Investors suffered damages when the market learned the truth about ChemoCentryx.